Discussion {#onco12378-sec-0006}
==========

Our study indicates that tolerance to the Bev‐TMZ combination was acceptable in this population. Hematological toxicity greater than grade 3 was reported in 20% of patients. As expected, the most frequent adverse event observed with Bev was high blood pressure, which responded to antihypertensive treatment. Although the rate of thromboembolic events does not appear to be exceedingly high in this bedridden GBM population, the two cases of intestinal perforation can be ascribed to Bev; furthermore, Bev may have played a role in the two cases of cerebral hemorrhage.

An objective radiological response in one third of patients and the fact that one third of patients also became autonomous and capable of self‐care (i.e., KPS \>70) is encouraging and in agreement with the observations of significant improvements in cognition and most quality‐of‐life scales during the treatment period. Additionally, the estimated OS median of 24 weeks (Figure [1](#onco12378-fig-0001){ref-type="fig"}) that we found appears higher that the 12 weeks OS that we found in a similar patient population treated with supportive care alone (personal data, unpublished).

![Kaplan‐Meier plot: experimental arm, primary assessment, total patient population. **(A)**: Kaplan‐Meier estimates of overall survival. **(B)**: Kaplan‐Meier estimates of progression‐free survival.](onco12378-fig-0001){#onco12378-fig-0001}

There was a trend for increased PFS and OS in patients with methylated promoter O‐6‐methylguanine‐DNA methyltransferase (MGMT) status; however, in contrast to our previous study that used TMZ alone, this difference did not reach statistical significance. This may reflect a lack of power. On the other hand, it is possible that some patients without methylated MGMT promoter also could benefit from Bev because its action is not believed to be influenced by MGMT methylation status.

Trial Information {#onco12378-sec-0007}
=================

**Disease**Brain cancer -- primary**Stage of Disease/Treatment**Primary**Prior Therapy**None**Type of Study ‐ 1**Phase II**Type of Study ‐ 2**Single arm**Primary Endpoint**Overall survival**Secondary Endpoint**Progression‐free survival**Secondary Endpoint**Tolerability**Secondary Endpoint**Health‐related quality of life**Secondary Endpoint**Cognitive functioning**Additional Details of Endpoints or Study Design** The primary endpoint was median OS, and the secondary endpoints were PFS, tolerance of treatment, health‐related quality of life (European Organisation for Research and Treatment of Cancer \[EORTC\] quality of life questionnaires: core questionnaire \[QLQ‐C30\], version 3.0, and brain cancer module \[QLQ‐BN20\]) and cognitive functioning (mini‐mental state examination \[MMSE\]). The sample size was based on the accuracy of the median survival estimation. Assuming a median survival of 22 weeks and a minimum follow‐up of 12 months, it was estimated that 70 patients were needed to evaluate survival with a half width of its 95% confidence interval of 14 weeks. All patients who received at least one dose of treatment were included in the analyses. OS was calculated from the date of surgery until death. PFS was defined as the time from surgery to the date of progression or death. The survival distributions were estimated by the Kaplan‐Meier method. The log‐rank test was used to compare OS and PFS according to MGMT status. Prognostic factors for survival were examined by a stepwise Cox regression model. The factors included in the model were age and KPS at inclusion (60 vs. \<60). A second Cox regression model was performed on the patients for whom MGMT promoter methylation assessment was available, with MGMT status, age, and KPS as covariates. Changes from baseline of health‐related quality of life scores, MMSE scores, and KPS were analyzed using a mixed‐model analysis, with time as a fixed effect and the patient as a random effect. Logistic regression was used to identify predictive factors of clinical improvement defined by a KPS ≥70 at two consecutive visits. All analyses were performed using SAS software version 8.2 (SAS Institute, Cary, NC). The α level was set at 0.05. Baseline assessments included physical and neurological examinations, assessments of KPS, health‐related quality of life questionnaires (EORTC QLQ‐C30, version 3.0, and QLQBN20), cognitive evaluations with MMSE, complete blood counts and blood chemistry tests, and contrast‐enhanced brain computed tomography or magnetic resonance imaging. Patients were assessed every 2 weeks by physical and neurological examinations, complete blood counts, and urine strip tests. The blood chemistry tests, quality of life assessments, KPS evaluations, and MMSEs were repeated every month. Neuroimaging studies were repeated every 2 months, and tumor response was assessed using the response assessment in neuro‐oncology criteria, taking into account the perpendicular diameters of the tumor in contrasted sequences and fluid‐attenuated inversion recovery. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. The EORTC QLQ‐C30 and QLQ‐BN20 were used to assess health‐related quality of life. The QLQ‐C30 questionnaire includes 30 questions comprising five functioning scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, vomiting, and pain), and six single‐item scales (dyspnea, insomnia, constipation, anorexia, diarrhea, and financial difficulties). The QLQ‐BN20 questionnaire includes 20 items covering functional deficits, symptoms, toxic effects of treatment, and uncertainty about the future. Questionnaires were filled out by patients when possible or by a companion (always the same) when the patient was unable to complete the form. The MMSE was used as a measure of general cognitive status. Higher scores on this exam, which uses a 30‐point scale, indicated better cognitive function. **Investigator\'s Analysis**Active and should be pursued further

Drug Information {#onco12378-sec-0008}
================

Drug 1 Generic/Working NameTemozolomideDrug TypeSmall moleculeDrug ClassAlkylating agentDose130--150 milligrams (mg) per square meter (m^2^)RouteOral (p.o.)Drug 2 Generic/Working NameBevacizumabDrug TypeAntibodyDrug ClassAngiogenesis -- VEGFDose10 mg milligrams (mg) per kilogram (kg)RouteIVSchedule of AdministrationEvery 2 weeks

Patient Characteristics {#onco12378-sec-0009}
=======================

Number of Patients, Male24Number of Patients, Female42AgeMedian (range): 76 years (70--87 years)Number of Prior Systemic TherapiesMedian: 0OtherThe median postoperative Karnofsky performance status was 60 (range, 30--60)

Primary Assessment Method {#onco12378-sec-0010}
=========================

TitleTotal Patient PopulationNumber of Patients Screened71Number of Patients Enrolled66Number of Patients Evaluable for Toxicity66Number of Patients Evaluated for Efficacy66Response Assessment CR*n* = 1Response Assessment PR*n* = 20Response Assessment SD*n* = 24Response Assessment PD*n* = 15(Median) Duration Assessments PFS15.3 weeks; CI, 12.9--19.3(Median) Duration Assessments OS23.9 weeks; CI, 19--27.6Kaplan‐Meier Time UnitsWeeks
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**Kaplan‐Meier Plot Legend**

Kaplan‐Meier estimates of overall survival (OS)

Phase II Experimental Adverse Events {#onco12378-sec-0012}
====================================

Tolerance to treatment was acceptable, and most adverse events (AEs) were mild to moderate. AEs of grade ≥3 were observed in 37 (56%) patients and are detailed in Table [2](#onco12378-tbl-0002){ref-type="table"}. High blood pressure was the most frequent AE and was detected in 16 (24%) patients. It was manageable with antihypertensive medication, and Bev discontinuation was not necessary in any of those cases. Hematological AEs of grade ≥3 were reported in 13 (20%) patients, including neutropenia (*n* = 2), anemia (*n* = 1), thrombocytopenia (*n* = 5), and lymphopenia (*n* = 8). Fatal myelosuppression was not observed. 

Serious Adverse Events {#onco12378-sec-1012}
======================
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**Serious Adverse Events Legend**

Serious adverse events included deep venous thrombosis (three cases), pulmonary embolism (two cases, including one fatal), intestinal perforation (two cases, including one fatal), and cerebral hemorrhage (two cases, including one fatal grade 5 toxicity).

Assessment, Analysis, and Discussion {#onco12378-sec-0014}
====================================

CompletionStudy completedInvestigator\'s AssessmentActive and should be pursued further

 {#onco12378-sec-0101}

Elderly patients aged 65 years and older account for approximately 45% of patients with glioblastoma multiforme (GBM) \[[1](#onco12378-bib-0001){ref-type="ref"}\], and this figure is expected to rise concurrently with the aging population of most countries \[[2](#onco12378-bib-0002){ref-type="ref"}\]. Unfortunately, few trials have been performed in this setting \[[3](#onco12378-bib-0003){ref-type="ref"}\], \[[4](#onco12378-bib-0004){ref-type="ref"}\], \[[5](#onco12378-bib-0005){ref-type="ref"}\], \[[6](#onco12378-bib-0006){ref-type="ref"}\], \[[7](#onco12378-bib-0007){ref-type="ref"}\]. In elderly patients with good functional status (Karnofsky performance status \[KPS\] \>70 or Eastern Cooperative Oncology Group score 0--2), the standard treatment is now the combination of radiotherapy (RT) and temozolomide (TMZ; concomitant and adjuvant). In elderly patients with poor functional status at the time of diagnosis (KPS \<70), there is no standard treatment. One trial suggested that accelerated 1‐week RT could be of help, but this trial mixed various populations, including younger patients and elderly patients in good clinical condition \[[8](#onco12378-bib-0008){ref-type="ref"}\]. In elderly, bedridden patients with unresectable GBM, the benefit of radiotherapy is unproven and questionable; indeed, it requires daily trips to the hospital, resulting in increased fatigue and an increased risk of acute complications, including intracranial hypertension and herniation, particularly when high doses per fraction are used. In this very difficult patient population, we previously showed that TMZ alone was associated with improvement in functional status in one third of cases and appeared to increase survival compared with supportive care alone \[[9](#onco12378-bib-0009){ref-type="ref"}\].

Bevacizumab (Bev) is an antiangiogenic monoclonal antibody targeting vascular endothelial growth factor that is commonly used in GBM. Although recent phase III studies did not show a significant effect of adding Bev to alkylating agents (TMZ or nitrosoureas) on overall survival (OS), a favorable impact of this combination on progression‐free survival was demonstrated both as a first‐line treatment and in the recurrent setting \[[10](#onco12378-bib-0010){ref-type="ref"}\], \[[11](#onco12378-bib-0011){ref-type="ref"}\], \[[12](#onco12378-bib-0012){ref-type="ref"}\], \[[13](#onco12378-bib-0013){ref-type="ref"}\], \[[14](#onco12378-bib-0014){ref-type="ref"}\], \[[15](#onco12378-bib-0015){ref-type="ref"}\], \[[16](#onco12378-bib-0016){ref-type="ref"}\].

Treatment of GBM in elderly patients with impaired functional status is challenging. In a recursive partitioning analysis, the estimated median OS in elderly patients with GBM with a KPS \<70 without surgical resection was only 10 weeks (95% CI, 9--13.5) \[[17](#onco12378-bib-0017){ref-type="ref"}\]. In a recent phase II trial focusing on this frail elderly population, we found that TMZ alone was helpful with a median OS of 25 weeks (95% CI, 19--28); 25% of patients became able to provide self‐care and had significant improvements in quality of life and cognition before disease progression \[[9](#onco12378-bib-0009){ref-type="ref"}\].

In this study, we evaluated the efficacy and safety of the upfront combination of TMZ + Bev as an initial treatment for elderly patients with GBM and impaired functional status (KPS \<70). Bev has a well‐known steroid‐sparing effect, presumably because of the blood‐brain and blood‐tumor barrier restoration \[[10](#onco12378-bib-0010){ref-type="ref"}\]. Indeed, corticosteroids could be reduced (in 56% of cases) or even discontinued (10%) in our patients with inoperable tumors. This steroid‐sparing effect is clearly favorable given the poor tolerance of elderly patients for steroids \[[18](#onco12378-bib-0018){ref-type="ref"}\].

Although the analysis included only 66 patients (5 patients were excluded because they did not take any dose of treatment), the precision obtained at the end of the trial of the estimation of the median survival was higher than expected (standard error of 5 weeks instead of 14 weeks). Additionally, the estimated OS median of 24 weeks that we found appears higher that the 12 weeks of OS that we found in a similar patient population treated with supportive care alone (personal data, unpublished). However, it is comparable to the 25 weeks that we reported in similar patients receiving TMZ alone \[[9](#onco12378-bib-0009){ref-type="ref"}\]. Whether this combination is superior to TMZ alone remains to be demonstrated by a randomized study.

Figures and Tables {#onco12378-sec-1117}
==================

###### Baseline patient characteristics

![](onco12378-tbl-0003){#nlm-graphic-9}

Abbreviations: Bev, bevacizumab; MMSE, mini‐mental state examination; TMZ, temozolomide.

###### Number of patients with grade ≥ 3 adverse events

![](onco12378-tbl-0004){#nlm-graphic-11}

###### Variations in MMSE and HRQoL scores over time before progression

![](onco12378-tbl-0005){#nlm-graphic-13}

Abbreviations: HRQoL, health‐related quality of life; MMSE, mini‐mental state examination; QLQ‐BN20, quality of life questionnaire, brain cancer module; QLQ‐C30, quality of life core questionnaire.

See <http://www.TheOncologist.com> for supplemental material available online.
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